Objectives of Study:
|
In a randomized, controlled study, patients with diabetic peripheral neuropathy were studied. Observe the compound live inunction limb, blood sugar complex ning sticking point after treatment in patients with Chinese medicine symptom integral, improve the degree of neuropathy (emg observation of sensory and motor nerve conduction velocity, pain, temperature sense, ankle cramps), oxidative stress index, the change of blood routine, liver and kidney function, evaluation of comprehensive therapy of traditional Chinese medicine in the treatment of DPN curative effect and security, Improve more evidence-based evidence for clinical programs.
|
Description for medicine or protocol of treatment in detail:
|
A total of 124 patients who met the inclusion criteria in the outpatient or inpatient department of secretion in Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine and cooperative Medical Care structure from January 2021 to December 2022 were selected and divided into treatment group and control group, with 62 patients in each group. Both groups received health education and basic treatment for diabetes. The course of treatment is 12 weeks.
Treatment group: mecobalamin (Bokebao), Eisai Hainan Star (China) Pharmaceutical Co., LTD.; Specification: 500 μg*30 pieces/board, 2 boards/box; National medicine approval word H20050997. Usage and dosage: oral, three times a day, one tablet each time, 12 weeks as a course of treatment. Take cotton balls to dip an appropriate amount of compound living blood (compound living blood composition: astragalus, safflower, corydalis, etc.), and apply compound living blood back and forth evenly to the affected limb, avoiding the skin damage. 3 minutes for each limb, once a day, 12 weeks for a course. Take eight wind, eight evil, hand sanli, Zusanli and other acupoints, take tangluoning (tangluoning composition: pepper, yanhusuo, vaseline, etc.) 5 grams evenly applied on the gauze, covered in eight wind and eight evil place, reserved for four hours, once a day.
Control group: mecobalamin (Bokebao), Eisai Hainan Star (China) Pharmaceutical Co., LTD.; Specification: 500 μg*30 pieces/board, 2 boards/box; National medicine approval word H20050997. Usage and Dosage: take it orally, one tablet each time, three times a day.
Blood routine examination, liver and kidney function, Michigan Neuropathy Screening Scale, quality of life specific scale for diabetic patients, Chinese medicine related signs, electromyography, serum SOD were observed.
|
Inclusion criteria
|
(1) Patients meeting the diagnostic criteria of diabetic peripheral neuropathy and TCM syndrome differentiation criteria;
(2) Aged between 18 and 80;
(3) HBA1c ≤10%, or fasting blood glucose ≤10mmol/L, 2h postprandial blood glucose ≤16mmol/L;
(4) Have enough education and understanding ability, and can easily communicate with researchers;
(5) Agree to keep the contract to participate in all clinical interview, examination and test steps required by the program, and sign the informed consent letter.
|
Exclusion criteria:
|
(1) suffering from mania, bipolar disorder or mental illness;
(2) have severe or unstable cardiovascular, liver, kidney, respiratory, or hematological disorders, symptomatic peripheral vascular diseases, or other physical disorders (including unstable hypertension) or psychological disorders that the investigator considers to be affecting study participation or likely to result in hospitalization during the study;
(3) have used drugs that are known to cause neuropathy (e.g., vincristine) and have suffered from diseases that may cause neuropathy, such as pernicious anaemia and hypothyroidism;
(4) Patients suffering from skin diseases or skin damage of limbs;
(5) Previous history of eye surgery;
(6) chronic inflammatory demyelinating polyneuropathy, cervical and lumbar lesions, cerebral infarction or Guillain-Barre syndrome;
(7) pregnant and lactating women;
(8) The staff of the research institution and their immediate family members who are directly related to the research;
(9) Unable to fill in various scales, or unwilling to be randomly grouped;
(10) patients who are participating in other clinical trials.
|